Literature DB >> 11251380

Alphavirus vectors: applications for DNA vaccine production and gene expression.

K Lundstrom1.   

Abstract

Replication-deficient alphavirus vectors have been developed for efficient high-level transgene expression. The broad host range of alphaviruses has allowed infection of a wide variety of mammalian cell lines and primary cultures. Particularly, G protein-coupled receptors have been expressed at high levels and subjected to binding and functional studies. Expression in suspension cultures has greatly facilitated production of large quantities of recombinant proteins for structural studies. Injection of recombinant alphavirus vectors into rodent brain resulted in local reporter gene expression. Highly neuron-specific expression was obtained in hippocampal slice cultures in vivo. Additionally, preliminary studies in animal models suggest that alphavirus vectors can be attractive candidates for gene therapy applications. Traditionally alphavirus vectors, either attenuated strains or replication-deficient particles, have been used to elicit efficient immune responses in animals. Recently, the application of alphaviruses has been extended to naked nucleic acids. Injection of DNA as well as RNA vectors has demonstrated efficient antigen production. In many cases, protection against lethal challenges has been obtained after immunization with alphavirus particles or nucleic acid vectors. Alphavirus vectors can therefore be considered as potentially promising vectors for vaccine production. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11251380     DOI: 10.1159/000053992

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  7 in total

1.  Structural genomics on membrane proteins: comparison of more than 100 GPCRs in 3 expression systems.

Authors:  Kenneth Lundstrom; Renaud Wagner; Christoph Reinhart; Aline Desmyter; Nadia Cherouati; Thierry Magnin; Gabrielle Zeder-Lutz; Melanie Courtot; Cécile Prual; Nicolas André; Gherici Hassaine; Hartmut Michel; Christian Cambillau; Franc Pattus
Journal:  J Struct Funct Genomics       Date:  2006-11-22

2.  Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.

Authors:  Yun-Zhou Yu; Yao Ma; Wen-Hui Xu; Shuang Wang; Zhi-Wei Sun
Journal:  Med Microbiol Immunol       Date:  2014-09-30       Impact factor: 3.402

3.  Self Replicating Gene Vaccine Carrying P1-2A Gene of FMDV Serotype O and its Effects on the Immune Responses of Cattle.

Authors:  G Nagarajan; P Ravikumar; C Ashok Kumar; G R Reddy; H J Dechamma; V V S Suryanarayana
Journal:  Indian J Virol       Date:  2011-05-10

4.  Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.

Authors:  H Ren; T Boulikas; K Lundstrom; A Söling; P C Warnke; N G Rainov
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

5.  Immunogenicity of a DNA-launched replicon-based canine parvovirus DNA vaccine expressing VP2 antigen in dogs.

Authors:  Shyam S Dahiya; Mohini Saini; Pankaj Kumar; Praveen K Gupta
Journal:  Res Vet Sci       Date:  2012-02-18       Impact factor: 2.534

Review 6.  Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases.

Authors:  Lu Yang; Lin Tang; Ming Zhang; Chaoyong Liu
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

Review 7.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.